Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLXNASDAQ:KMDANASDAQ:NGNENASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$2.97+2.2%$3.27$1.60▼$5.89$102.60M-0.36208,784 shs28,717 shsKMDAKamada$6.64$6.69$4.74▼$9.16$381.96M1.0785,672 shs20,423 shsNGNENeurogene$13.63-6.0%$13.89$6.88▼$74.49$203.36M1.46229,738 shs45,910 shsSAGESage Therapeutics$7.68-1.2%$7.54$4.62▼$14.71$471.87M0.481.21 million shs333,191 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+0.69%+7.41%-5.84%-26.02%-14.71%KMDAKamada-0.75%+3.75%-1.63%-3.21%+28.93%NGNENeurogene-5.91%+20.63%-0.14%-6.33%-51.60%SAGESage Therapeutics-0.26%+4.44%-6.16%+5.71%-43.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNLXGenelux1.9378 of 5 stars3.62.00.00.03.80.00.0KMDAKamada3.9842 of 5 stars3.55.00.00.02.81.72.5NGNENeurogene2.3501 of 5 stars3.60.00.00.03.41.71.3SAGESage Therapeutics3.5132 of 5 stars3.02.00.04.02.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.20Buy$18.25515.51% UpsideKMDAKamada 3.00Buy$14.67120.88% UpsideNGNENeurogene 3.14Buy$47.20246.19% UpsideSAGESage Therapeutics 2.00Hold$8.8114.82% UpsideCurrent Analyst Ratings BreakdownLatest GNLX, KMDA, NGNE, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.003/21/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.003/6/2025KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/12/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$14.00 ➝ $12.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$8K12,825.11N/AN/A$0.73 per share4.06KMDAKamada$160.95M2.37$0.37 per share17.90$4.25 per share1.56NGNENeurogene$925K220.06N/AN/A$14.51 per share0.94SAGESage Therapeutics$41.24M11.44N/AN/A$7.56 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$28.30M-$0.96N/AN/AN/AN/A-105.05%-80.16%5/8/2025 (Estimated)KMDAKamada$8.28M$0.2623.7320.750.979.92%6.30%4.49%5/6/2025 (Estimated)NGNENeurogene-$36.32M-$4.27N/AN/AN/AN/A-32.81%-27.96%5/9/2025 (Estimated)SAGESage Therapeutics-$400.67M-$6.59N/AN/AN/A-971.50%-68.18%-60.84%4/29/2025 (Estimated)Latest GNLX, KMDA, NGNE, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07N/AN/AN/A$154.06 millionN/A5/9/2025Q1 2025NGNENeurogene-$1.05N/AN/AN/AN/AN/A5/8/2025N/AGNLXGenelux-$0.24N/AN/AN/AN/AN/A4/29/2025Q1 2025SAGESage Therapeutics-$1.00N/AN/AN/A$14.12 millionN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million2/11/2025Q4 2024SAGESage Therapeutics-$1.54-$1.56-$0.02-$1.56$14.37 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ALatest GNLX, KMDA, NGNE, and SAGE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A6.476.47KMDAKamadaN/A4.842.73NGNENeurogeneN/A9.099.09SAGESage TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%KMDAKamada20.38%NGNENeurogene52.37%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipGNLXGenelux9.30%KMDAKamada36.10%NGNENeurogene9.92%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1034.60 million31.33 millionNot OptionableKMDAKamada36057.48 million36.73 millionOptionableNGNENeurogene9014.93 million13.38 millionOptionableSAGESage Therapeutics69061.48 million58.10 millionOptionableGNLX, KMDA, NGNE, and SAGE HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities InvestigationApril 29 at 10:00 AM | accessnewswire.comBoothbay Fund Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)April 28 at 6:46 AM | marketbeat.comRenaissance Technologies LLC Sells 62,505 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)April 28 at 3:36 AM | marketbeat.comExpert Outlook: Sage Therapeutics Through The Eyes Of 4 AnalystsApril 27 at 4:38 PM | nasdaq.comNeedham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE)April 27 at 8:29 AM | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Walleye Capital LLCApril 27 at 4:03 AM | marketbeat.comBrokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Target Price at $8.81April 25, 2025 | americanbankingnews.comNew Hope for Advanced Cancer Patients: SAGE Showcases Treatment-Matching via Functional Precision Oncology at AACR 2025April 24, 2025 | finance.yahoo.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationApril 24, 2025 | accessnewswire.comSage Therapeutics (SAGE) Projected to Post Quarterly Earnings on TuesdayApril 23, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of "Hold" by AnalystsApril 23, 2025 | marketbeat.comKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmApril 22, 2025 | prnewswire.comSage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseApril 22, 2025 | zacks.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the InvestigationApril 22, 2025 | accessnewswire.comSage, Biogen's zuranolone looks approvable, but will it sell?April 22, 2025 | pharmaphorum.comSage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationApril 20, 2025 | accessnewswire.comQ1 EPS Estimate for Sage Therapeutics Raised by AnalystApril 20, 2025 | marketbeat.comWedbush Research Analysts Raise Earnings Estimates for SAGEApril 20, 2025 | americanbankingnews.comQ1 Earnings Forecast for SAGE Issued By WedbushApril 19, 2025 | marketbeat.comQ1 Earnings Estimate for Sage Therapeutics Issued By WedbushApril 19, 2025 | americanbankingnews.comBronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to ConnectApril 17, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNLX, KMDA, NGNE, and SAGE Company DescriptionsGenelux NASDAQ:GNLX$2.96 +0.07 (+2.24%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Kamada NASDAQ:KMDA$6.64 0.00 (0.00%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Neurogene NASDAQ:NGNE$13.63 -0.87 (-5.97%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Sage Therapeutics NASDAQ:SAGE$7.68 -0.10 (-1.22%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
